Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset ra

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte

HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy an

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and main

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lower

Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the anal

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part o

- Orphan drug designation from the European Commission underscores Solid's commitment to advance

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and rai

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy a

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) wit

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.53) per share which missed the anal

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and raise

Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious des

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date -- Robust micro

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and main

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines

Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines

- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences co

- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing

- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing

'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screeni

Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, cit

Needham analyst Gil Blum initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating

Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences com

- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to An

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences co

Citigroup analyst Yigal Nochomovitz maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and lowe

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and low

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biote

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines